2022
Posttraumatic Stress Disorder in US Military Veterans: Results From the 2019-2020 National Health and Resilience in Veterans Study.
Wisco BE, Nomamiukor FO, Marx BP, Krystal JH, Southwick SM, Pietrzak RH. Posttraumatic Stress Disorder in US Military Veterans: Results From the 2019-2020 National Health and Resilience in Veterans Study. The Journal Of Clinical Psychiatry 2022, 83 PMID: 35192748, DOI: 10.4088/jcp.20m14029.Peer-Reviewed Original ResearchConceptsUS military veteransPosttraumatic stress disorderLifetime posttraumatic stress disorderFunctional impairmentMilitary veteran populationNational HealthMilitary veteransVeteran populationVeterans StudyTrauma exposureStress disorderGreater functional impairmentPTSD Criterion ALife Events Checklist-5Odds of lifetimeWeighted prevalencePTSD prevalenceIndirect trauma exposurePTSD ChecklistPrevalenceImpairmentPsychiatric variablesVeteransContemporary dataCriterion A
2014
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Current Pharmaceutical Design 2014, 20: 5077-92. PMID: 24345265, PMCID: PMC4442779, DOI: 10.2174/1381612819666131216121019.Peer-Reviewed Original ResearchConceptsCognitive impairmentStandardized cognitive test batteryCognitive test batteryInformation processing impairmentsNicotinic medicationsProcessing impairmentsCore deficitAttentional deficitsTest batteryCognitive deficitsProximal measuresBrain functionCognitionSchizophreniaDeficitsImpairmentNumber of medicationsNicotinic acetylcholine receptorsCertain symptomsConsistent improvementClinical evidenceTreatment strategiesClinical studiesNicotinic receptorsClinical utility
2013
Translational cognitive neuroscience of schizophrenia: bridging neurocognitive and computational approaches toward understanding cognitive deficits
Anticevic A, Krystal J, Barch D. Translational cognitive neuroscience of schizophrenia: bridging neurocognitive and computational approaches toward understanding cognitive deficits. 2013, 193-230. DOI: 10.1017/cbo9781139003872.013.Peer-Reviewed Original ResearchCognitive deficitsCognitive neuroscienceCourse of impairmentSevere mental illnessDeficitsSchizophreniaMental illnessPharmacological techniquesBiological contributionPrecise mechanismNeuroscienceIllnessLittle disputeRelated featuresStyleFunctional implicationsImpairmentManagement optionsImplicationsDisabilityPatientsSymptomsCliniciansDisease
2008
Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry 2008, 64: 4-10. PMID: 18466880, PMCID: PMC2577821, DOI: 10.1016/j.biopsych.2008.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsBiomedical ResearchBrainCognition DisordersCooperative BehaviorDrug IndustryHumansNational Institute of Mental Health (U.S.)Neuropsychological TestsResearch Support as TopicSchizophreniaSchizophrenic PsychologyUnited StatesUnited States Food and Drug AdministrationConceptsCognitive Neuroscience Treatment ResearchSchizophrenia (MATRICS) initiativeTreatment researchCognitive neuroscience fieldCNTRICS initiativeCognitive mechanismsCognitive constructsTreatment developmentNeuroscience fieldCognitive impairmentCognitionBasic animalSchizophreniaResearchFirst meetingImpairmentConstructsParadigmTranslational researchTranslation effortsNovel treatmentsOrganization
2005
Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia
Cho RY, Ford JM, Krystal JH, Laruelle M, Cuthbert B, Carter CS. Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia. Schizophrenia Bulletin 2005, 31: 865-869. PMID: 16166611, DOI: 10.1093/schbul/sbi050.Peer-Reviewed Original ResearchConceptsFunctional neuroimagingCognitive impairmentCognitive processesNeurobiological indicesTest-retest reliabilityCognitive functionTreatment researchDiscrepant findingsCognitionMental healthAdditional basic researchSchizophreniaNeuroimagingNovel pharmacotherapeuticsImpairmentParadigmResearchParticipantsBasic researchNIMHMatricFindingsRelative advantagesTrialsPerspective
1998
Complications of alcohol withdrawal: pathophysiological insights.
Trevisan LA, Boutros N, Petrakis IL, Krystal JH. Complications of alcohol withdrawal: pathophysiological insights. Alcohol Research 1998, 22: 61-6. PMID: 15706735, PMCID: PMC6761825.Peer-Reviewed Original ResearchConceptsAcute alcohol withdrawalAlcohol withdrawalLong-term sobrietyDelirium tremensAcute withdrawalMental confusionSignificant illnessPathophysiological insightsDisease processPsychiatric problemsCognitive impairmentComplicationsHeavy drinkingMemory disordersWithdrawalDeliriumMedicationsRelapseTremensPatientsSeizuresIllnessImpairmentSeverityHallucinationsInteractive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal J, Karper L, Bennett A, D’Souza D, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner J, Bowers Jr. M, Suckow R, Stetson P, Heninger G, Charney D. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998, 135: 213-229. PMID: 9498724, DOI: 10.1007/s002130050503.Peer-Reviewed Original ResearchConceptsWisconsin Card Sorting TestClinician-Administered Dissociative States ScalePerceptual alterationsAmnestic effectsInteractive effectsCard Sorting TestBrief Psychiatric Rating ScaleAttention impairmentSorting TestPerceptual effectsProverb interpretationEmotional distressDissociative effectsCortical impairmentNegative symptomsState scaleBehavioral effectsTest dayPsychiatric Rating ScaleLorazepam 2ImpairmentRating ScaleSubanesthetic ketamineHealthy humansPlacebo 2
1997
Neuroscience: implications for treatment.
Petrakis I, Krystal J. Neuroscience: implications for treatment. Alcohol Research 1997, 21: 157-60. PMID: 15704353, PMCID: PMC6826829.Peer-Reviewed Original Research